TY - JOUR
T1 - Lenalidomide for second-line treatment of advanced hepatocellular cancer
T2 - A brown university oncology group phase II study
AU - Safran, Howard
AU - Charpentier, Kevin P.
AU - Kaubisch, Andreas
AU - Mantripragada, Kalyan
AU - Dubel, Gregory
AU - Perez, Kimberly
AU - Faricy-Anderson, Katherine
AU - Miner, Thomas
AU - Eng, Yoko
AU - Victor, Joel
AU - Plette, Angela
AU - Espat, Joseph
AU - Bakalarski, Pamela
AU - Wingate, Patti
AU - Berz, David
AU - Luppe, Denise
AU - Martel, Diane
AU - Rosati, Kayla
AU - Aparo, Santiago
N1 - Publisher Copyright:
© 2014 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/2/2
Y1 - 2015/2/2
N2 - Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.
AB - Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.
KW - Lenalidomide
KW - hepatocellular cancer
KW - sorafenib
UR - http://www.scopus.com/inward/record.url?scp=84964211517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964211517&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3182868c66
DO - 10.1097/COC.0b013e3182868c66
M3 - Article
C2 - 23648434
AN - SCOPUS:84964211517
SN - 0277-3732
VL - 38
SP - 1
EP - 4
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -